

BRIEF SUMMARY**For Intravenous Infusion Only****DESCRIPTION**

Adenosine is an endogenous nucleoside occurring in all cells of the body. It is chemically 6-amino-9-beta-D-ribofuranosyl-9-H-purine. Adenosine is a white crystalline powder. It is soluble in water and practically insoluble in alcohol. Solubility increases by warming and lowering the pH of the solution. Each Adenoscan vial contains a sterile, non-pyrogenic solution of adenosine 3 mg/mL and sodium chloride 9 mg/mL in Water for Injection, q.s. The pH of the solution is between 4.5 and 7.5.

INDICATIONS AND USAGE:

Intravenous Adenoscan is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

(See WARNINGS).**CONTRAINDICATIONS:**

Intravenous Adenoscan should not be administered to individuals with:

1. Second- or third-degree AV block (except in patients with a functioning artificial pacemaker).
2. Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker).
3. Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma).
4. Known hypersensitivity to adenosine.

WARNINGS:**Fatal Cardiac Arrest, Life Threatening Ventricular Arrhythmias, and Myocardial Infarction.**

Fatal cardiac arrest, sustained ventricular tachycardia (requiring resuscitation), and nonfatal myocardial infarction have been reported coincident with Adenoscan infusion. Patients with unstable angina may be at greater risk. Appropriate resuscitative measures should be available.

Sinoatrial and Atrioventricular Nodal Block

Adenoscan exerts a direct depressant effect on the SA and AV nodes and has the potential to cause first-, second- or third-degree AV block, or sinus bradycardia. Approximately 6.3% of patients develop AV block with Adenoscan, including first-degree (2.9%), second-degree (2.6%) and third-degree (0.8%) heart block. All episodes of AV block have been asymptomatic, transient, and did not require intervention. Adenoscan can cause sinus bradycardia. Adenoscan should be used with caution in patients with pre-existing first-degree AV block or bundle branch block and should be avoided in patients with high-grade AV block or sinus node dysfunction (except in patients with a functioning artificial pacemaker). Adenoscan should be discontinued in any patient who develops persistent or symptomatic high-grade AV block. Sinus pause has been rarely observed with adenosine infusions.

Hypotension

Adenoscan is a potent peripheral vasodilator and can cause significant hypotension. Patients with an intact baroreceptor reflex mechanism are able to maintain blood pressure and tissue perfusion in response to Adenoscan by increasing heart rate and cardiac output. However, Adenoscan should be used with caution in patients with autonomic dysfunction, stenotic valvular heart disease, pericarditis or pericardial effusions, stenotic carotid artery disease with cerebrovascular insufficiency, or uncorrected hypovolemia, due to the risk of hypotensive complications in these patients. Adenoscan should be discontinued in any patient who develops persistent or symptomatic hypotension.

Hypertension

Increases in systolic and diastolic pressure have been observed (as great as 140 mm Hg systolic in one case) concomitant with Adenoscan infusion; most increases resolved spontaneously within several minutes, but in some cases, hypertension lasted for several hours.

Bronchoconstriction

Adenoscan is a respiratory stimulant (probably through activation of carotid body chemoreceptors) and intravenous administration in man has been shown to increase minute ventilation (V_e) and reduce arterial PCO₂, causing respiratory alkalosis. Approximately 28% of patients experience breathlessness (dyspnea) or an urge to breathe deeply with Adenoscan. These respiratory complaints are transient and only rarely require intervention.

Adenosine administered by inhalation has been reported to cause bronchoconstriction in asthmatic patients, presumably due to mast cell degranulation and histamine release. These effects have not been observed in normal subjects. Adenoscan has been administered to a limited number of patients with asthma and mild to moderate exacerbation of their symptoms has been reported. Respiratory compromise has occurred during adenosine infusion in patients with obstructive pulmonary disease. Adenoscan should be used with caution in patients with obstructive lung disease not associated with bronchoconstriction (e.g., emphysema, bronchitis, etc.) and should be avoided in patients with bronchoconstriction or bronchospasm (e.g., asthma). Adenoscan should be discontinued in any patient who develops severe respiratory difficulties.

PRECAUTIONS:**Drug Interactions**

Intravenous Adenoscan has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenoscan should be used with caution in the presence of these agents. The vasoactive effects of Adenoscan are inhibited by adenosine receptor antagonists, such as methylxanthines (e.g., caffeine and theophylline). The safety and efficacy of Adenoscan in the presence of these agents has not been systematically evaluated. The vasoactive effects of Adenoscan are potentiated by nucleoside transport inhibitors, such as dipyridamole. The safety and efficacy of Adenoscan in the presence of dipyridamole has not been systematically evaluated. Whenever possible, drugs that might inhibit or augment the effects of adenosine should be withheld for at least five half-lives prior to the use of Adenoscan.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies in animals have not been performed to evaluate the carcinogenic potential of Adenoscan. Adenosine was negative for genotoxic potential in the Salmonella (Ames Test) and Mammalian Microsome Assay. Adenosine, however, like other nucleosides at millimolar concentrations present for several doubling times of cells in culture, is known to produce a variety of chromosomal alterations. Fertility studies in animals have not been conducted with adenosine.

Pregnancy Category C

Animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. Because it is not known whether Adenoscan can cause fetal harm when administered to pregnant women, Adenoscan should be used during pregnancy only if clearly needed.

Pediatric Use

The safety and effectiveness of Adenoscan in patients less than 18 years of age have not been established.

Geriatric Use

Clinical studies of Adenoscan did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. Other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients. Greater sensitivity of some older individuals, however, cannot be ruled out.

ADVERSE REACTIONS:

The following reactions with an incidence of at least 1% were reported with intravenous Adenoscan among 1421 patients enrolled in controlled and uncontrolled U.S. clinical trials. Despite the short half-life of adenosine, 10.6% of the side effects occurred not with the infusion of Adenoscan but several hours after the infusion terminated. Also, 8.4% of the side effects that began coincident with the infusion persisted for up to 24 hours after the infusion was complete. In many cases, it is not possible to know whether these late adverse events are the result of Adenoscan infusion.

Flushing	44%	Gastrointestinal discomfort	13%	Second-degree AV block	3%
Chest discomfort	40%	Lightheadedness/dizziness	12%	Paresthesia	2%
Dyspnea or urge to breathe deeply	28%	Upper extremity discomfort	4%	Hypotension	2%
Headache	18%	ST segment depression	3%	Nervousness	2%
Throat, neck or jaw discomfort	15%	First-degree AV block	3%	Arrhythmias	1%

Adverse experiences of any severity reported in less than 1% of patients include:

Body as a Whole: back discomfort; lower extremity discomfort; weakness.

Cardiovascular System: nonfatal myocardial infarction; life-threatening ventricular arrhythmia; third-degree AV block; bradycardia; palpitation; sinus exit block; sinus pause; sweating; T-wave changes; hypertension (systolic blood pressure > 200 mm Hg).

Central Nervous System: drowsiness; emotional instability; tremors.

Genital/Urinary System: vaginal pressure; urgency.

Respiratory System: cough.

Special Senses: blurred vision; dry mouth; ear discomfort; metallic taste; nasal congestion; scotomas; tongue discomfort.

Post Marketing Experience (see WARNINGS): The following adverse events have been reported from marketing experience with Adenoscan. Because these events are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, (3) strength of causal connection to the drug, or a combination of these factors.

Body as a Whole: Injection site reaction

Central Nervous System: Seizure activity, including tonic clonic (grand mal) seizures, and loss of consciousness

Digestive: Nausea and vomiting

Respiratory: Respiratory arrest

OVERDOSAGE:

The half-life of adenosine is less than 10 seconds and side effects of Adenoscan (when they occur) usually resolve quickly when the infusion is discontinued, although delayed or persistent effects have been observed. Methylxanthines, such as caffeine and theophylline, are competitive adenosine receptor antagonists and theophylline has been used to effectively terminate persistent side effects. In controlled U.S. clinical trials, theophylline (50-125 mg slow intravenous injection) was needed to abort Adenoscan side effects in less than 2% of patients.

DOSAGE AND ADMINISTRATION:

For intravenous infusion only.

Adenoscan should be given as a continuous peripheral intravenous infusion.

The recommended intravenous dose for adults is 140 mcg/kg/min infused for six minutes (total dose of 0.84 mg/kg).

The required dose of thallium-201 should be injected at the midpoint of the Adenoscan infusion (i.e., after the first three minutes of Adenoscan).

Thallium-201 is physically compatible with Adenoscan and may be injected directly into the Adenoscan infusion set.

The injection should be as close to the venous access as possible to prevent an inadvertent increase in the dose of Adenoscan (the contents of the IV tubing) being administered. There are no data on the safety or efficacy of alternative Adenoscan infusion protocols.

The safety and efficacy of Adenoscan administered by the intracoronary route have not been established.

Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

Rx only

Marketed by Astellas Pharma US, Inc.

Deerfield, IL 60015

Manufactured by Hospira Inc.

Lake Forest, IL 60045 USA

47101/Revised: September 2006

Aspiration During PCI Improves Reperfusion

BY TIMOTHY F. KIRN

Sacramento Bureau

Manual aspiration of atherothrombotic debris during percutaneous coronary intervention improved myocardial reperfusion and decreased ST-segment elevation, compared with PCI alone in a randomized controlled trial of patients with possible MIs.

After conventional PCI, 26% of patients had a myocardial blush grade of 0 or 1; but after PCI with thrombus aspiration, 17% of patients had grades of 0 or 1, reported Dr. Tone Svilaas and his colleagues, from the University Medical Center Groningen, the Netherlands. A 70% or greater resolution of ST-segment elevation was seen in 57% of the patients treated with aspiration and in 44% of the patients treated with ballooning and stent placement alone (N. Engl. J. Med. 2008;358:557-67).

Deaths and major cardiac events at 30 days were significantly related to myocardial blush grade and resolution of ST-segment elevation. At 30 days, 2% of the aspiration group and 4% of the conventional PCI group had died and 4% and 3%, respectively, had a major bleeding event. Major adverse cardiac events occurred in 7% and 9%, respectively.

All patients can potentially benefit from aspiration, they said. "Our data show that angiographic variables such as TIMI flow or the presence of visible thrombus are not predictors of patients in whom aspiration will be effective."

In a commentary accompanying the report, Dr. George W. Vetrovec said thrombus extraction is "conceptually sound and

appears to reduce the risk." In an interview, however, Dr. Vetrovec of the Virginia Commonwealth University, Richmond, Pauley Heart Center expressed concern about the impact of the additional process on door-to-balloon time. Although aspiration has not increased door-to-balloon time in his personal experience, widespread use might be associated with longer times, and that possibility needs to be evaluated, he said.

For their study, Dr. Svilaas and his colleagues enrolled 1,071 consecutive patients with a possible MI with ST-segment elevation seen at the center during 2005-2006. All had symptoms lasting more than 30 minutes, and an onset lasting less than 12 hours, and an ST-segment elevation of more than 0.1 mV in two or more leads on ECG. The mean age of the patients was 63 years, and about 70% were male.

Patients were randomized prior to angiography. All had a guidewire introduced through their occlusion. The patients who received aspiration PCI had a 6-French Export Aspiration Catheter (Medtronic) advanced into the coronary segment during continuous aspiration.

The median time from baseline to post-procedural ECG was 44 minutes for the aspiration group and 43 minutes for the conventional PCI group.

An examination of the aspiration contents indicated atherothrombotic material was present in 73% of the 454 aspiration cases examined. The contents consisted of platelets alone in 68% of cases, a thrombus with bands of erythrocytes in 15% of cases, and a thrombus with various components in 17% of cases. ■

CABG Bests Drug-Eluting Stents in Multivessel Disease, Registry Shows

Coronary artery bypass grafting produces better outcomes than drug-eluting coronary stents do in patients with multivessel disease, according to a database study.

Given recent reports of the danger of late stent thrombosis with the drug-eluting devices, it wasn't clear "whether the relative outcomes reported in earlier studies that compared coronary artery bypass grafting (CABG) with coronary stenting are reflective of current practice." Most of those studies were done comparing CABG with bare metal stents.

So Dr. Edward L. Hannan of the State University of New York at Albany and his associates used public health databases to compare outcomes between 9,963 state residents who received multiple drug-eluting stents via percutaneous coronary intervention and 7,437 who underwent CABG between October 2003 and December 2004. They followed all subjects through the end of 2005 and presented their report in the Jan. 24 issue of the New England Journal of Medicine.

Patients who received stents had a low-

er survival rate at 18 months (93%) than did those who underwent CABG (94%), as well as lower rates of the combined end point of freedom from MI or death (88% vs. 92%, respectively).

Outcomes were superior with CABG regardless of whether patients had proximal left anterior descending artery disease. And there was a trend favoring CABG in three high-risk subgroups of patients: those with diabetes, those with left ventricular ejection fractions below 40%, and those aged 80 and older, Dr. Hannan and his associates said (N. Engl. J. Med. 2008; 358:331-41).

In an accompanying editorial comment, Dr. Joseph P. Carrozza Jr. of Harvard Medical School, Boston, said, "The New York state registries are a sobering reality check for those who hoped the benefits of drug elution would level the playing field between CABG and stents." Instead, the results "affirm that CABG remains the standard of care for patients who require multivessel coronary revascularization," he said (New Engl. J. Med. 2008;358:405-7).

—Mary Ann Moon